Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Uveal Melanoma × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Lung Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Triple Negative Breast Neoplasms 2 Pancreatic Neoplasms 2 Colorectal Neoplasms 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Small Cell Lung Carcinoma 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Oropharyngeal Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Microsatellite Instability 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large B-Cell, Diffuse 1 Liver Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Cancer Female 1 Adenocarcinoma of Lung 1 Adenocarcinoma Of Esophagus 1

Interventions

trametinib 2 olaparib 1 glembatumumab vedotin 1 durvalumab 1 cediranib 1 Vorinostat 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Ipilimumab 1 CTLA-4 Antigen 1 CR011-vcMMAE 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04184518 2020-06-02

CEDUVEAL-M

Grupo Español Multidisciplinar de Melanoma

Phase 2 Withdrawn

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡